Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097868 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL887512 | 1.00 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL13930001 | 0.97 | SLC6A11 (0.36) | SLC6A1SLC6A11PBRM1KIF11ALDH1A1 | |
| SCHEMBL2472575 | 0.91 | SLC6A11 (0.35) | SLC6A1SLC6A11PBRM1KIF11ALDH1A1 | |
| SCHEMBL13498579 | 0.91 | SLC6A1 (0.32) | SLC6A1SLC6A11 | |
| SCHEMBL16329608 | 0.90 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL2820572 | 0.90 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL27050962 | 0.90 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL25764740 | 0.90 | SLC6A1 (0.34) | SLC6A1SLC6A11PBRM1TK2KIF11 | |
| SCHEMBL10159580 | 0.90 | PBRM1 (0.34) | SLC6A1SLC6A11PBRM1KIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689116-A1 | VEHICLES FOR DELIVERING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | claimed |
| WO-2024199445-A1 | VEHICLES FOR DELIVERING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2024-10-03 | — | — | WO | claimed |
| EP-4367244-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2024-05-15 | — | — | EP | claimed |
| CN-117916374-A | Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117821443-A | Medium for efficiently purifying nucleic acid and preparation method | 苏州吉玛基因股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2023280190-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2023-01-12 | — | — | WO | claimed |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SYNERK BIOTECH LTD (HK) | 2026-02-12 | — | — | US | disclosed |
| EP-4689116-A1 | VEHICLES FOR DELIVERING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | disclosed |
| WO-2024199445-A1 | VEHICLES FOR DELIVERING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2024-10-03 | — | — | WO | disclosed |
| EP-4367244-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-117916374-A | Oligonucleotide-based delivery vehicles for oligonucleotide agents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4352225-A1 | MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING | Intellia Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117821443-A | Medium for efficiently purifying nucleic acid and preparation method | 苏州吉玛基因股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023280190-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022261292-A1 | MODIFIED GUIDE RNAS COMPRISING AN INTERNAL LINKER FOR GENE EDITING | INTELLIA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | VITRISA THERAPEUTICS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180127754-A1 | BIVALENT ANTISENSE OLIGONUCLEOTIDES | MIRRX THERAPEUTICS A/S (DK) | 2018-05-10 | — | — | US | disclosed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | MTREX, DCLRE1B, ADAR | SLC6A1 4633/4885SLC6A11 4520/4885PBRM1 1425/4885 |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SSU72, NSUN2, RNMT | SLC6A1 4336/4885SLC6A11 4269/4885PBRM1 2144/4885 |
| US-10308943-B2 | Compositions with improved intravitreal half-life and uses thereof | UACA, CRYAA, CRYAB | SLC6A1 3842/4885SLC6A11 3649/4885PBRM1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.